BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Multispan, Inc. Announces Co-Marketing Plan With Molecular Devices Corporation (MDCC)


9/26/2006 1:11:56 PM

HAYWARD, Calif., Sept. 26 /PRNewswire/ -- Multispan Inc., a technology platform company specializing in G-Protein-Coupled Receptor (GPCR) research, today announced the launch of a series of co-marketing campaigns with Molecular Devices Corp. , the leading manufacturer of instrumentation and reagents for GPCR research.

Multispan and Molecular Devices have recently completed an intensive evaluation of Molecular Devices' latest product for GPCR screening, the FLIPR(R) Calcium 4 Assay Kit for GPCRs. The evaluation consisted of utilizing Multispan's GPCR compound profiling panel and GPCR stable cell-lines to compare the Ca++ detection of FLIPR Calcium 4 Assay Kit with competitor kits over 48 Multispan receptors. The results indicated that the FLIPR Calcium 4 Assay Kit had superior overall performance over the previous Molecular Devices' FLIPR Calcium and Calcium 3 Assay Kits and those from competitors.

Under the terms of this co-marketing program, Multispan has agreed to actively promote Molecular Devices' FLIPR(R) Calcium 4 Assay Kit to its partners and customers, in conjunction with Molecular Devices' promotion of Multispan's GPCR compound profiling service and stable cell-line assays to its customer base. Both companies will create literature and web links to support the campaign.

"Molecular Devices has been the product leader and provider of instruments and reagents for GPCR drug discovery over the past decade. Multispan's GPCR biological assay platform shares great synergy with Molecular Devices products for Ca++ detection," said Helena Mancebo, Chief Executive Officer at Multispan. "We are thrilled to have them as a partner."

About Multispan: Multispan Inc. is a San Francisco Bay Area-based biotechnology company focused exclusively on GPCRs, the most important protein class of therapeutic targets. Privately held, and founded in 2004, Multispan has created the industry's largest collection of human GPCR expression clones and has engineered a large collection of assays for GPCR drug screening with its proprietary high expression technology for multi-trans-membrane proteins.

About Molecular Devices: Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.

For further information, please visit our website (www.multispaninc.com) or contact Helena Mancebo (helena.mancebo@multispaninc.com)

Multispan Inc.

CONTACT: Helena Mancebo, Ph.D., President and CEO of Multispan, Inc.,+1-510-887-0817, ext 101, or cell, +1-510-396-5452, or fax,+1-510-887-0863, or Helena.Mancebo@Multispaninc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES